

Special Issue

Targeting Angiogenic Pathways and Combination Approaches

Message from the Guest Editors

The aim of this Special Issue is to draw attention to vascular targeting approaches and increase knowledge on the combination of this strategy with other cancer therapies, such as immune-, chemo-, radio- and photodynamic therapies. The Special Issue aims to publish a collection of original research articles and reviews. Potential topics may include (but are not limited to):

- New strategies for targeting the tumor vasculature.
- Combination strategies of anti-angiogenic therapy and other anti-cancer approaches.
- Enhanced insight in the mechanisms of angiogenesis and anti-angiogenesis.
- In vitro, preclinical and clinical approaches of anti-angiogenesis and combination therapies.

Guest Editors

Prof. Dr. Patrycja Nowak-Sliwinska

1. Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland
2. Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland
3. Translational Research Center in Oncohaematology, 1211 Geneva, Switzerland

Prof. Dr. Arjan Griffioen

Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/175529

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)